Cannabinoids and Their Potential in Inflammatory and Metabolic Conditions

While preliminary research into cannabinoid compounds shows promise for treating widespread conditions, clinicians should exercise caution in translating these findings into practice given the typically small sample sizes, short follow-up periods, and mechanistic uncertainty that characterize early-stage cannabis research. The gap between “may help” in laboratory or animal models and clinical efficacy in real patients remains substantial, and most cannabis-based interventions lack the robust evidence standards required for confident therapeutic recommendation. Additionally, patient access to standardized, quality-controlled cannabis products varies widely by jurisdiction, and concurrent use with other medications may create unpredictable interactions that complicate treatment plans. Until larger, well-designed clinical trials establish clear efficacy and optimal dosing, the most prudent clinical approach is to remain appropriately skeptical of media reports about cannabis as a disease-reversing agent while staying informed about evolving evidence. When patients raise questions about cannabis for their condition, providers can acknowledge the